Immunogenicity of quadrivalent HPV and combined hepatitis A and B vaccine when co-administered or administered one month apart to 9-10 year-old girls according to 0-6 month schedule

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 8, 2014, Pages 2438-2445

  Gilca, Vladimir ^a,b,c   Sauvageau, Chantal ^a,b,c   Boulianne, Nicole ^a,b,c   De Serres, Gaston ^a,b,c   Couillard, Michel ^d   Krajden, Mel ^e   Ouakki, Manale ^a,b   Murphy, Donald ^d   Trevisan, Andrea ^d   Dionne, Marc ^a,b,c  

^a Quebec Public Health Institute   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c University Laval   (Canada)

^d Quebec Public Health Laboratory   (Canada)

^e BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

Author keywords

Hepatitis A and B; HPV; Immunogenicity; Two doses; Vaccination

Indexed keywords

HEPATITIS A ANTIBODY; HEPATITIS A HEPATITIS B VACCINE; HEPATITIS B ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY; WART VIRUS ANTIBODY; WART VIRUS VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; HUMAN PAPILLOMAVIRUS VACCINE L1, TYPE 6,11,16,18; VACCINE;

ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CHILD; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; HEPATITIS A; HEPATITIS B; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNE RESPONSE; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MONOTHERAPY; OPEN STUDY; PAPILLOMAVIRUS INFECTION; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; VACCINATION; BLOOD; CLINICAL TRIAL; IMMUNIZATION; IMMUNOLOGY; PAPILLOMAVIRUS INFECTIONS;

ANTIBODIES, VIRAL; CHILD; FEMALE; HEPATITIS A; HEPATITIS A VACCINES; HEPATITIS B; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION SCHEDULE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; VACCINES, COMBINED;

EID: 84908431501     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.29617     Document Type: Article

References (35)

1. Plotkin SA, Orenstein WA, Offit PA. Vaccines. Sixth Edition ed. Philadelphia: Saunders Elsevier; 2012.
2. Villa LL. Prophylactic HPV vaccines: Reducing the burden of HPV-related diseases. Vaccine 2006; 24:S-23-8; PMID:16194583
3. GlaxoSmithKline. Cervarix - Efficacity and Immunogenicity. GSKVaccinesDirect.com 2013; https://www.gskvaccines.ca/gsk.ca/CA/htdocs/products/CERVARIX/product-info-efficacy.htm. Accessed July 10th, 2013.
4. Kreimer AR, Rodriguez AC, Hildesheim A, Herrero R, Porras C, Schiffman M, González P, Solomon D, Jiménez S, Schiller JT, et al.; CVT Vaccine Group. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst 2011; 103:1444-51; PMID:21908768; http://dx.doi.org/10.1093/jnci/djr319
5. Einstein MH, Baron M, Levin MJ, Chatterjee A, Fox B, Scholar S, Rosen J, Chakhtoura N, Meric D, Dessy FJ, et al.; HPV-010 Study Group. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years. Hum Vaccin 2011; 7:1343-58; PMID:22048173; http://dx.doi.org/10.4161/hv.7.12.18281
6. Safaeian M, Porras C, Pan Y, Kreimer A, Schiller JT, Gonzalez P, Lowy DR, Wacholder S, Schiffman M, Rodriguez AC, et al.; CVT Group. Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial. Cancer Prev Res (Phila) 2013; 6:1242-50; PMID:24189371; http://dx.doi.org/10.1158/1940-6207.CAPR-13-0203
7. Pedersen C, Petaja T, Strauss G, Rumke HC, Poder A, Richardus JH, Spiessens B, Descamps D, Hardt K, Lehtinen M, et al.; HPV Vaccine Adolescent Study Investigators Network. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health 2007; 40:564-71; PMID:17531764; http://dx.doi.org/10.1016/j.jadohealth.2007.02.015
8. Dobson SRM, McNeil S, Dionne M, Dawar M, Ogilvie G, Krajden M, Sauvageau C, Scheifele DW, Kollmann TR, Halperin SA, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA 2013; 309:1793-802; PMID:23632723; http://dx.doi.org/10.1001/jama.2013.1625
9. Gilca V, Dionne M, Boulianne N, Murphy D, De Wals P, De Serres G. Immunogenicity of two peadiatric doses of Twinrix and Recombivax-HB and the effect of a booster dose given seven years later. Poster presentation. 27th Annual Meeting of the European Society for Paediatric Infectious Diseases. Belgium, Brussels", June 9-13. 2009.
10. Van Damme P, Van der Wielen M. Combining hepatitis A and B vaccination in children and adolescents. Vaccine 2001; 19:2407-12; PMID:11257370; http://dx.doi.org/10.1016/S0264-410X(00)00464-3
11. Smolen KK, Gelinas L, Franzen L, Dobson S, Dawar M, Ogilvie G, Krajden M, Fortuno ES 3rd, Kollmann TR. Age of recipient and number of doses differentially impact human B and T cell immune memory responses to HPV vaccination. Vaccine 2012; 30:3572-9; PMID:22469863; http://dx.doi.org/10.1016/j.vaccine.2012.03.051
12. Romanowski B, Schwarz TF, Ferguson LM, Peters K, Dionne M, Schulze K, Ramjattan B, Hillemanns P, Catteau G, Dobbelaere K, et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study. Hum Vaccin 2011; 7:1374-86; PMID:22048171; http://dx.doi.org/10.4161/hv.7.12.18322
13. Lamontagne DS, Thiem VD, Huong VM, Tang Y, Neuzil KM. Immunogenicity of quadrivalent HPV vaccine among girls 11 to 13 Years of age vaccinated using alternative dosing schedules: results 29 to 32 months after third dose. J Infect Dis 2013; 208:1325-34; PMID:23901077; http://dx.doi.org/10.1093/infdis/jit363
14. Van Damme P, Leroux-Roels G, Law B, Diaz-Mitoma F, Desombere I, Collard F, Tornieporth N, Van Herck K. Long-term persistence of antibodies induced by vaccination and safety follow-up, with the first combined vaccine against hepatitis A and B in children and adults. J Med Virol 2001; 65:6-13; PMID:11505437; http://dx.doi.org/10.1002/jmv.1094
15. Wheeler CM, Bautista OM, Tomassini JE, Nelson M, Sattler CA, Barr E; Protocol 11 study Investigators. Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines. Vaccine 2008; 26:686-96; PMID:18164106; http://dx.doi.org/10.1016/j.vaccine.2007.11.043
16. Schmeink CE, Bekkers RL, Josefsson A, Richardus JH, Berndtsson Blom K, David MP, Dobbelaere K, Descamps D. Co-administration of human papillomavirus-16/18 AS04-adjuvanted vaccine with hepatitis B vaccine: randomized study in healthy girls. Vaccine 2011; 29:9276-83; PMID:21856349; http://dx.doi.org/10.1016/j.vaccine.2011.08.037
17. Block SL, Nolan T, Sattler C, Barr E, Giacoletti KE, Marchant CD, Castellsagué X, Rusche SA, Lukac S, Bryan JT, et al.; Protocol 016 Study Group. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006; 118:2135-45; PMID:17079588; http://dx.doi.org/10.1542/peds.2006-0461
18. Duval B, Gîlca V, Boulianne N, Deceuninck G, Rochette L, De Serres G. Immunogenicity of two paediatric doses of monovalent hepatitis B or combined hepatitis A and B vaccine in 8-10-year-old children. Vaccine 2005; 23:4082-7; PMID:15963363; http://dx.doi.org/10.1016/j.vaccine.2004.07.022
19. Gilca V, De Serres G, Boulianne N, Murphy D, De Wals P, Ouakki M, Trudeau G, Massé R, Dionne M. Antibody persistence and the effect of a booster dose given 5, 10 or 15 years after vaccinating preadolescents with a recombinant hepatitis B vaccine. Vaccine 2013; 31:448-51; PMID:23206974; http://dx.doi.org/10.1016/j.vaccine.2012.11.037
20. Gilca V, De Serres G, Boulianne N, Murphy D, Ouakki M, De Wals P, Trudeau G, Massé R, Dionne M. Long-term persistence of immunity after vaccination of pre-adolescents with low doses of a recombinant hepatitis B vaccine. Hum Vaccin Immunother 2013; 9:1685-90; PMID:23744506; http://dx.doi.org/10.4161/hv.25015
21. Krajden M, Cook D, Yu A, Chow R, Su Q, Mei W, McNeil S, Money D, Dionne M, Palefsky J, et al. Assessment of HPV 16 and HPV 18 antibody responses by pseudovirus neutralization, Merck cLIA and Merck total IgG LIA immunoassays in a reduced dosage quadrivalent HPV vaccine trial. Vaccine 2014; 32:624-30; PMID:24055350; http://dx.doi.org/10.1016/j.vaccine.2013.09.007
22. European, Consensus, Group. Are booster immunisations needed for lifelong hepatitis B immunity? Lancet 2000; 355:561-5; PMID:10683019; http://dx.doi.org/10.1016/S0140-6736(99)07239-6
23. Hammitt LL, Bulkow L, Hennessy TW, Zanis C, Snowball M, Williams JL, Bell BP, McMahon BJ. Persistence of antibody to hepatitis A virus 10 years after vaccination among children and adults. J Infect Dis 2008; 198:1776-82; PMID:18976095; http://dx.doi.org/10.1086/593335
24. Wolters B, Müller T, Ross RS, Clauberg R, Werfel U, Roggendorf H, Siggelkow C, Hausen T, Roggendorf M. Comparative evaluation of the immunogenicity of combined hepatitis A and B vaccine by a prospective and retrospective trial. Hum Vaccin 2009; 5:248-53; PMID:19276678; http://dx.doi.org/10.4161/hv.5.4.7051
25. Bian GL, Ma R, Dong HJ, Ni HX, Hu FJ, Chen YR, Chen JQ, Zhou SY, Lin YX, Xu GZ. Long-term clinical observation of the immunogenicity of inactivated hepatitis A vaccine in children. Vaccine 2010; 28:4798-801; PMID:20471440; http://dx.doi.org/10.1016/j.vaccine.2010.04.096
26. Schwarz TF, Spaczynski M, Schneider A, Wysocki J, Galaj A, Schulze K, Poncelet SM, Catteau G, Thomas F, Descamps D. Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15-55 years. Hum Vaccin 2011; 7:958-65; PMID:21892005; http://dx.doi.org/10.4161/hv.7.9.15999
27. Dobson SR, McNeil S, Dionne M, Dawar M, Ogilvie G, Krajden M, Sauvageau C, Scheifele DW, Kollmann TR, Halperin SA, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA 2013; 309:1793-802; PMID:23632723; http://dx.doi.org/10.1001/jama.2013.1625
28. Brown B, Blas M, Cabral A, Carcamo C, Gravitt P, Halsey N. Randomized trial of HPV4 vaccine assessing the response to HPV4 vaccine in two schedules among Peruvian female sex workers. Vaccine 2012; 30:2309-14; PMID:22306855; http://dx.doi.org/10.1016/j.vaccine.2012.01.058
29. Joura EA, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, et al. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine 2008; 26:6844-51; PMID:18930097; http://dx.doi.org/10.1016/j.vaccine.2008.09.073
30. Bonanni P, Boccalini S, Bechini A. Efficacy, duration of immunity and cross protection after HPV vaccination: a review of the evidence. Vaccine 2009; 27(Suppl 1):A46-53; PMID:19480962; http://dx.doi.org/10.1016/j.vaccine.2008.10.085
31. Yoshikawa H, Ebihara K, Tanaka Y, Noda K. Efficacy of quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine (GARDASIL) in Japanese women aged 18-26 years. Cancer Sci 2013; 104:465-72; PMID:23331518; http://dx.doi.org/10.1111/cas.12106
32. Li R, Li Y, Radley D, Liu Y, Huang T, Sings HL, Zhang L, Wang W, Zhong X, Saah AJ. Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, double-blind, placebo-controlled trial in Chinese males and females. Vaccine 2012; 30:4284-91; PMID:22433961; http://dx.doi.org/10.1016/j.vaccine.2012.02.079
33. Watson-Jones D, Brown J, Baisley K, Balthazar B. Kapiga S. [Internet]. Impact of malaria and helminth infections on HPV vaccine innunogenicity in Tanzanian females. 28th International Papillomavirus Conference - Puerto Rico CLINICAL SCIENCE New vaccine trials (Phase I-III; preventive and therapeutic trials) Page 209. Available from http://www.hpv2012pr.org/HPV2012-PUERTO-RICO-Abstract%20Clinical-Sciences.pdf Accessed on December 2, 2013.
34. Ministère de la Santé et des Services sociaux. Virus du papillome humain [En ligne] http://www.msss.gouv.qc.ca/sujets/santepub/vaccination/index.php?programme-de-vaccination-contre-le-vph (Page accédée le 5 juin 2014).
35. World Health Organisation. Immunization, Vaccines and Biologicals - Summary of the SAGE April 2014 meeting. [On line] http://www.who.int/immunization/sage/meetings/2014/april/report-summary-april-2014/en/ (Page accessed June 5, 2014).